Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FGFR mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related biomarkers:

‹

›

FGFR mutation	Cholangiocarcinoma	FGFR mutation	Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) erdafitinib Sensitive : C3 ASCO-GI 2023 - 2wk	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks erdafitinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR mutation	Urothelial Cancer	FGFR mutation	Urothelial Cancer	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2
FGFR mutation	Urothelial Cancer	FGFR mutation	Urothelial Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR mutation	Pancreatic Cancer	FGFR mutation	Pancreatic Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR mutation	Urothelial Cancer	FGFR mutation	Urothelial Cancer	erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials erdafitinib + JNJ-63723283 Sensitive : C3	erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials erdafitinib + JNJ-63723283 Sensitive : C3
FGFR mutation	Urothelial Cancer	FGFR mutation	Urothelial Cancer	FGFR inhibitor Sensitive: C3 – Early Trials FGFR inhibitor Sensitive : C3	FGFR inhibitor Sensitive: C3 – Early Trials FGFR inhibitor Sensitive : C3
FGFR mutation	Solid Tumor	FGFR mutation	Solid Tumor	ICP-192 Sensitive: C3 – Early Trials ICP-192 Sensitive : C3	ICP-192 Sensitive: C3 – Early Trials ICP-192 Sensitive : C3
FGFR mutation	Cholangiocarcinoma	FGFR mutation	Cholangiocarcinoma	ponatinib Sensitive: C3 – Early Trials ponatinib Sensitive : C3	ponatinib Sensitive: C3 – Early Trials ponatinib Sensitive : C3
FGFR mutation	Cholangiocarcinoma	FGFR mutation	Cholangiocarcinoma	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR mutation	Non Small Cell Lung Cancer	FGFR mutation	Non Small Cell Lung Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR mutation	Astrocytoma	FGFR mutation	Astrocytoma	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR mutation	Uterine Cancer	FGFR mutation	Uterine Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR mutation	Gallbladder Cancer	FGFR mutation	Gallbladder Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR mutation	Head and Neck Cancer	FGFR mutation	Head and Neck Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR mutation	Salivary Gland Cancer	FGFR mutation	Salivary Gland Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR mutation	Pancreatic Cancer	FGFR mutation	Pancreatic Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR mutation	Glioblastoma	FGFR mutation	Glioblastoma	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR mutation	Breast Cancer	FGFR mutation	Breast Cancer	E7090 Sensitive: D – Preclinical E7090 Sensitive : D	E7090 Sensitive: D – Preclinical E7090 Sensitive : D